These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 28453946)

  • 21. Genitourinary Syndrome of Menopause.
    Shifren JL
    Clin Obstet Gynecol; 2018 Sep; 61(3):508-516. PubMed ID: 29787390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause.
    Biehl C; Plotsker O; Mirkin S
    Menopause; 2019 Apr; 26(4):431-453. PubMed ID: 30363010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conjugated estrogens (Premarin) vaginal cream.
    Med Lett Drugs Ther; 2009 Feb; 51(1306):14-5. PubMed ID: 19229162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review.
    Simon JA; Goldstein I; Kim NN; Davis SR; Kellogg-Spadt S; Lowenstein L; Pinkerton JV; Stuenkel CA; Traish AM; Archer DF; Bachmann G; Goldstein AT; Nappi RE; Vignozzi L
    Menopause; 2018 Jul; 25(7):837-847. PubMed ID: 29870471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hormonal Medications for Genitourinary Syndrome of Menopause.
    Pinkerton JV; Vaughan MH; Kaunitz AM
    Clin Obstet Gynecol; 2024 Mar; 67(1):68-78. PubMed ID: 38032827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genitourinary syndrome of menopause and the use of laser therapy.
    Hutchinson-Colas J; Segal S
    Maturitas; 2015 Dec; 82(4):342-5. PubMed ID: 26323234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics, pharmacodynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause.
    Bondi C; Ferrero S; Scala C; Tafi E; Racca A; Venturini PL; Leone Roberti Maggiore U
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1233-46. PubMed ID: 27476551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treating genitourinary syndrome of menopause in breast cancer survivors: main challenges and promising strategies.
    Castelo-Branco C; Mension E; Torras I; Cebrecos I; Anglès-Acedo S
    Climacteric; 2023 Aug; 26(4):296-301. PubMed ID: 36946290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Female Pelvic Conditions: Genitourinary Syndrome of Menopause.
    Brady PH; Gin GT; Rosenblum E; Wilkinson LD
    FP Essent; 2022 Apr; 515():32-42. PubMed ID: 35420405
    [No Abstract]   [Full Text] [Related]  

  • 30. Genitourinary syndrome of menopause: a systematic review on prevalence and treatment.
    Mili N; Paschou SA; Armeni A; Georgopoulos N; Goulis DG; Lambrinoudaki I
    Menopause; 2021 Mar; 28(6):706-716. PubMed ID: 33739315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MsFLASH network vaginal health trial: absence of evidence is NOT evidence of absence.
    Lukas VA; Simon JA
    Menopause; 2020 Jun; 27(6):722-725. PubMed ID: 32068684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of low dose estrogen therapy on the vaginal microbiomes of women with atrophic vaginitis.
    Shen J; Song N; Williams CJ; Brown CJ; Yan Z; Xu C; Forney LJ
    Sci Rep; 2016 Apr; 6():24380. PubMed ID: 27103314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An overview of dehydroepiandrosterone (EM-760) as a treatment option for genitourinary syndrome of menopause.
    Holton M; Thorne C; Goldstein AT
    Expert Opin Pharmacother; 2020 Mar; 21(4):409-415. PubMed ID: 31928093
    [No Abstract]   [Full Text] [Related]  

  • 34. Aloe Vera; A new treatment for atrophic vaginitis, A randomized double-blinded controlled trial.
    Poordast T; Ghaedian L; Ghaedian L; Najib FS; Alipour S; Hosseinzadeh M; Vardanjani HM; Salehi A; Hosseinimehr SJ
    J Ethnopharmacol; 2021 Apr; 270():113760. PubMed ID: 33383112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.
    Wurz GT; Kao CJ; DeGregorio MW
    Clin Interv Aging; 2014; 9():1939-50. PubMed ID: 25419123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dynamic quadripolar radiofrequency treatment of vaginal laxity/menopausal vulvo-vaginal atrophy: 12-month efficacy and safety.
    Vicariotto F; DE Seta F; Faoro V; Raichi M
    Minerva Ginecol; 2017 Aug; 69(4):342-349. PubMed ID: 28608667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?
    Edwards D; Panay N
    Climacteric; 2016 Apr; 19(2):151-61. PubMed ID: 26707589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society.
    North American Menopause Society
    Menopause; 2007; 14(3 Pt 1):355-69; quiz 370-1. PubMed ID: 17438512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CO
    Athanasiou S; Pitsouni E; Falagas ME; Salvatore S; Grigoriadis T
    Maturitas; 2017 Oct; 104():24-28. PubMed ID: 28923173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Managing postmenopausal vaginal atrophy. Vaginal dryness is one of the most irritating symptoms of menopause. Here are some ways to relieve it.
    Harv Womens Health Watch; 2010 Mar; 17(7):4-5. PubMed ID: 20480969
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.